EBUS-TNBA 22G samples: Comparison of PD-L1 expression between DAKO and BIOCARE®

Konstantinos Sapalidis; Paul Zarogoulidis; Dimitris Petridis; Christoforos Kosmidis; Barbara Fyntanidou; Kosmas Tsakiridis; Elena Maragouli; Aikaterini Amaniti; Dimitris Giannakidis; Charilaos Koulouris; Stylianos Mantalobas; Athanasios Katsaounis; Vyron Alexandrou; Georgios Koimtzis; Efstathios Pavlidis; Anastasios Barmpas; Theodora Tsiouda; Chrysanthi Sardeli; Zoi Aidoni; Haidong Huang; Qiang Li; Wolfgang Hohenforst-Schmidt; Isaak Kesisoglou

doi:10.7150/jca.35898

EBUS-TNBA 22G samples: Comparison of PD-L1 expression between DAKO and BIOCARE^®

J Cancer. 2019 Aug 20;10(20):4739-4746. doi: 10.7150/jca.35898. eCollection 2019.

Authors

Konstantinos Sapalidis¹, Paul Zarogoulidis¹, Dimitris Petridis², Christoforos Kosmidis¹, Barbara Fyntanidou¹, Kosmas Tsakiridis¹, Elena Maragouli¹, Aikaterini Amaniti³, Dimitris Giannakidis¹, Charilaos Koulouris¹, Stylianos Mantalobas¹, Athanasios Katsaounis¹, Vyron Alexandrou¹, Georgios Koimtzis¹, Efstathios Pavlidis¹, Anastasios Barmpas¹, Theodora Tsiouda⁴, Chrysanthi Sardeli⁵, Zoi Aidoni⁶, Haidong Huang⁷, Qiang Li⁷, Wolfgang Hohenforst-Schmidt⁸, Isaak Kesisoglou¹

Affiliations

¹ 3rd Department of Surgery, "AHEPA" University Hospital, Aristotle University of Thessaloniki, Medical School, Thessaloniki, Greece.
² Department of Food Technology, School of Food Technology and Nutrition, Alexander Technological Educational Institute, Thessaloniki, Greece.
³ Anesthisiology Department, "AHEPA" University Hospital, Aristotle University of Thessaloniki, Medical School, Thessaloniki, Greece.
⁴ Pulmonary Oncology Department, "Theageneio" Cancer Hospital, Thessaloniki, Greece.
⁵ Intensive Care Unit, "AHEPA" University Hospital, Aristotle University of Thessaloniki, Medical School, Thessaloniki, Greece.
⁶ Department of Pharmacology & Clinical Pharmacology, School of Medicine, Faculty of Health Sciences, Aristotle University of Thessaloniki, Thessaloniki, Greece.
⁷ The Diagnostic and Therapeutic Center of Respiratory Diseases, Shanghai East Hospital, Tongji University, Shanghai, China.
⁸ Sana Clinic Group Franken, Department of Cardiology / Pulmonology / Intensive Care / Nephrology, "Hof" Clinics, University of Erlangen, Hof, Germany.

Abstract

Introduction: Lung cancer is diagnosed at advanced stage due to lack of early disease symptoms. Currently we have several different biopsy techniques such as; radial endobronchial ultrasound, convex probe endobronchial ultrasound, electromagnetic navigation, ct guided biospy and transthoracic ultrasound biopsy. Novel therapies such as; immunotherapy is being used for non-small cell lung cancer in the everyday clinical practice as first and second line treatment. Programmed ligand-1 is essential in order to administer immunotherapy as first line treatment. Patients and Methods: Two thousands and two patients were included in our study where programmed ligand 1 was evaluated with DAKO technique and BIOCARE^®. Cell blocks were obtain with convex probe ebus-tbna 22G needle. Results: The Deming regression between DAKO and BIOCARE clone revealed an amazingly strong linear relationship as the coefficient of determination indicated (R²=0.999) and the variance ratio close to 1 (0.978), proving that both techniques can equally well be substituted for each other. The regression coefficient equals to 1 and the intercept hardly differs from 0 (0.936). In practice, this relationship permits adopting the economically affordable BIOCARE clone for further medical considerations. Conclusion: No statistical difference was observed between DAKO and BIOCARE^®, therefore we propose that both techniques can be used in order to investigate the expression of programmed ligand 1 with safety. PD-L1 expression was higher in the central mass instead of the lymphnodes.

Keywords: NSCLC; PD-L1; convex probe EBUS; lung cancer; lymph nodes.